Establishment of a Neutrophil elastase Activity home test for the Better management and treatment of Lung Exacerbations

Project Information

ENABLE

Grant agreement ID: 651158

DOI 10.3030/651158

Project closed

EC signature date 26 September 2014

Start date 1 October 2014

End date 31 March 2015

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

PROAXSIS LTD
United Kingdom

Objective

Chronic obstructive airways disease (COPD) is a leading cause of death of increasing prevalence worldwide and is characterised by progressive airflow reduction, breathing difficulties and irreversible lung damage. Management of COPD varies extensively, with patients not receiving proactive disease management at greater risk of poorer outcomes. Routine measurement of an active protease (enzyme) biomarker called neutrophil elastase (NE) will empower clinicians and patients to adopt proactive approaches to disease management and treatment, reducing exacerbations and emergency hospital admissions.

Our goal is therefore to develop a novel, simple to use ‘Point-of-Care’ (PoC) test that will improve patient outcome and reduce the clinical, societal and economic burdens associated with chronic respiratory disease (CRD). The activity of NE (NEa) in the airways is known to correlate with the severity of several CRDs such as COPD, cystic fibrosis (CF) and bronchiectasis, and importantly is highly predictive of infection and an early marker of exacerbation. Our novel device, NEATstikTM (Neutrophil Elastase Airways Test), will enable the rapid measurement of NEa at PoC and has been designed for home use (patient self-management) in mind, with a view to remote monitoring. It is expected that this test will help to improve patient management and outcome, with the ultimate goal of reducing the individual, European and global burden of COPD.

This phase 1 proposal is to provide a feasibility assessment which will maximise the potential for success the clinical validation of NEATstikTM, a PoC device that will enable the proactive management of chronic respiratory diseases such as COPD.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• medical and health sciences › health sciences › infectious diseases › RNA viruses › coronaviruses
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antibiotics
• medical and health sciences › clinical medicine › oncology
• social sciences › economics and business › economics › health economics
• natural sciences › biological sciences › biochemistry › biomolecules › proteins › enzymes

You need to log in or register to use this function

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Topic(s)

• PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Call for proposal

H2020-SMEInst-2014-2015

See other projects for this call

Sub call

H2020-SMEINST-1-2014

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

PROAXSIS LTD

• Net EU contribution: € 50 000,00
• Address: 63 University Road ; BT7 1NF Belfast ; United Kingdom
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  Northern Ireland › Northern Ireland › Belfast
• Region: Northern Ireland › Northern Ireland › Belfast
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 71 429,00